))
Biologic Therapy in Rheumatoid Arthritis: Pioneers in Research, is a monthly series of podcasts featuring interviews with today's giants in rheumatology sponsored by Schering-Plough Corporation. In this series brought to you by Rheumatology News International, you will hear some of the greatest scientists in rheumatology describe the exploration of what was then uncharted medical territory. Their words will bring alive the journey of discovery that placed them in the annals of history's grea ...
…
continue reading
A series of free podcasts featuring news and expert interviews focused on treating patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other rheumatic diseases.
…
continue reading
Recent Advances in RA, features a telephone interview with Professor Josef Smolen由rhnews@elsevier.com (Rheumatology News International)
…
continue reading
1
Episode 5: Novel Endpoints in RA Diagnosis and Management Monitoring Anemia, Fatigue, and Cardiovascular Status
16:07
Novel Endpoints in RA Diagnosis and Management: Monitoring Anemia, Fatigue, and Cardiovascular Status, features a telephone interview with Professor Iain McInnes.由rhnews@elsevier.com (Rheumatology News International)
…
continue reading
1
Episode 4: Treatment Needs in Patients with Psoriatic Arthitis features a telephone interview with Professor Douglas Veale
14:43
Treatment Needs in Patients with Psoriatic Arthitis features a telephone interview with Professor Douglas Veale由rhnews@elsevier.com (Rheumatology News International)
…
continue reading
1
Episode 3: How Would Early Treatment Affect Disease and Quality-of-Life Outcomes in Spondyloarthritis (SpA)
14:43
This podcast, How Would Early Treatment Affect Disease and Quality-of-Life Outcomes in Spondyloarthritis (SpA)?, features a telephone interview with Professor Joachim Sieper.由rhnews@elsevier.com (Rheumatology News International)
…
continue reading
This podcast, Predicting the Onset and Disease Course of Rheumatoid Arthritis, features a telephone interview with Professor Lars Klareskog.由rhnews@elsevier.com (Rheumatology News International)
…
continue reading
This first podcast in a new series titled Patient Impressions of Biologic Treatment for RA: Highlights from the RAISE Study features an interview with Professor Haraoui. He reviews a review a new study that allows rheumatologists to predict the value of using combined treatment in patients based on disease markers.…
…
continue reading
This sixth podcast program, Individualizing Therapy: Today’s Options, Tomorrow’s Opportunities, features an interview with Professor McInnes. He discusses the current state of knowledge in rheumatoid arthritis and directions for discovery in coming years.由rhnews@elsevier.com (Rheumatology News International)
…
continue reading
This fifth podcast titled Progress and Prognosis: Evaluating Patients’ Responses to Biologic Therapy features a telephone interview with Professor Schett. He discusses differences among the anti-TNF agents in the treatment of rheumatoid arthritis.由rhnews@elsevier.com (Rheumatology News International)
…
continue reading
1
Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity
14:21
Professor VonVollenhoven discusses factors which distinguish individual responses by patients with rheumatoid arthritis to various anti-TNF agents. He describes observations of radiologic and clinical progression of illness in subgroups of patients and provides an overview of considerations in choosing one pharmacologic agent over another. Professo…
…
continue reading
1
Episode 3: Anti-TNF Treatment: Focus on early Rheumatoid Arthritis. Featuring an interview with Professor Paul Emery
14:21
Contemporary research shows that the early diagnosis and treatment of RA can offer patients the possibility of achieving remission. The goal for any patient with early RA should be to achieve remission. If a patient does not already have joint damage, the goal should be a normal acute-phase response and no swollen joints as soon as possible.…
…
continue reading
Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only clinical improvement but also slow the radiographic progression of joint disease and damage. Further, the combination …
…
continue reading
Professor Sir Ravinder Maini's groundbreaking work on the characterization of TNF-alpha began in the mid-1980's with his collaboration with Professor Mark Feldman. In his study of intercellular messenger molecules, Professor Sir Maini utilized two new technologies -- protein sequencing and cDNA protein coding -- to investigate half a dozen cytokine…
…
continue reading
